Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Colorectal cancer (CRC) is the third most common type of cancer and the second leading
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Since the discovery of an oncogenic tropomyosin-receptor kinase (TRK) fusion protein in the
early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) …

Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1,
and previously induced deep [objective response rate (ORR) 57.4%] and durable [median …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

Highlights•NTRK gene fusions are oncogenic drivers in a variety of tumor types including
adult and pediatric sarcomas.•TRK inhibitors provide effective treatment options for patients …

Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …

PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase
(TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers …